Is Wegovy Better Than Zepbound? Plus the First Obesity GLP-1 Generic is Here!
Update: 2025-09-02
Description
This episode of On The Pen: The Weekly Dose Podcast breaks down four major stories in obesity medicine: the FDA’s approval of Teva’s so-called “generic” Saxenda at a sky-high price, Wegovy’s accelerated approval in MASH, Novo Nordisk’s headline-grabbing but shaky 57% cardiovascular benefit claim, and Eli Lilly’s decision to scrap its oral GLP-1 naperiglipron. We cut through the spin to ask what these developments really mean for patients fighting for access and better treatment options.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
